ProShares Ultra NASDAQ Biotechnology
BIB
BIB
34 hedge funds and large institutions have $13.8M invested in ProShares Ultra NASDAQ Biotechnology in 2019 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
32% less call options, than puts
Call options by funds: $5.57M | Put options by funds: $8.24M
Holders
34
Holding in Top 10
–
Calls
$5.57M
Puts
$8.24M
Top Buyers
| 1 | +$2.84M | |
| 2 | +$1.59M | |
| 3 | +$263K | |
| 4 |
SW
SlateStone Wealth
Jupiter,
Florida
|
+$258K |
| 5 |
MC
Moors & Cabot
Boston,
Massachusetts
|
+$207K |
Top Sellers
| 1 | -$4.21M | |
| 2 | -$655K | |
| 3 | -$605K | |
| 4 |
BRC
Bell Rock Capital
Rehoboth Beach,
Delaware
|
-$442K |
| 5 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$140K |